US OptionsDetailed Quotes

BPMC241220P80000

Watchlist

0.10
0.000.00%

15min DelayClose Dec 13 16:00 ET

0.00High0.00Low

Blueprint Medicines Stock Discussion

Stock_Drift

Apr 11 20:13

Extended Hours Top Moovers.

$Gryphon Digital Mining (GRYP.US)$ $Zimmer Biomet Holdings (ZBH.US)$ $Cohu Inc (COHU.US)$ $Evolv Technologies (EVLV.US)$ $Brookfield (BN.US)$ $VACASA INC (VCSA.US)$ $Blueprint Medicines (BPMC.US)$ $Williams-Sonoma (WSM.US)$ $U.S. Century Bank (USCB.US)$
📊⚡️📊

frankinglily

Apr 1 03:50

Updated Complete & Utter M&A Guesses Purely for Entertainment Purposes:

$SPDR S&P Biotech ETF (XBI.US)$
$Merck & Co (MRK.US)$ x $Immunovant (IMVT.US)$
$Eli Lilly and Co (LLY.US)$ x $Cytokinetics (CYTK.US)$ (and soon)
$Regeneron Pharmaceuticals (REGN.US)$ x $Apellis Pharmaceuticals (APLS.US)$ (panache & brash)
$Gilead Sciences (GILD.US)$ x % $Madrigal Pharmaceuticals (MDGL.US)$ (liver king)
$Bristol-Myers Squibb (BMY.US)$ x $Iovance Biotherapeutics (IOVA.US)$ (cell Tx boost needed)
$Eli Lilly and Co (LLY.US)$ x $Merus (MRUS.US)$ (partner n...

Moomoo AI

Mar 15 06:44

Insiders selling shares without any recorded purchases over the last year raises caution. The alignment between management and smaller shareholders due to insider ownership is not outstanding. Caution is advised before buying shares in Blueprint Medicines due to significant selling activity.

Possible Bearish Signals With Blueprint Medicines Insiders Disposing Stock

Moomoo AI

Feb 19 12:10

The stock's commendable performance is tied to revenue growth. However, profitability and cash flow checks are crucial for future views. Given the strong share price momentum, the stock warrants a closer look.

Blueprint Medicines (NASDAQ:BPMC) Delivers Shareholders Decent 95% Return Over 1 Year, Surging 16% in the Last Week Alone

Moomoo AI

Jan 29 09:59

Blueprint Medicines' high P/S ratio is worrisome due to its lower projected growth compared to the broader industry. If future revenues don't support this optimism, the current high P/S ratio may not be sustainable. Prices may not be reasonable unless conditions significantly improve.

Blueprint Medicines Corporation's (NASDAQ:BPMC) Shareholders Might Be Looking For Exit

Moomoo AI

Dec 18, 2023 08:23

Blueprint Medicines' increased debt brings a heightened risk profile due to last year's dilution in revenues and lack of profitability. Its future earnings and balance sheet health are key to assessing risk.

Health Check: How Prudently Does Blueprint Medicines (NASDAQ:BPMC) Use Debt?

Moomoo AI

Nov 14, 2023 06:44

Significant sale by President of R&D Fouad Namouni implies shares may not be undervalued. This, along with multiple insider sales, is a potential red flag for investors.

Blueprint Medicines Insiders Sold US$2.1m Of Shares Suggesting Hesitancy

Moomoo AI

Oct 17, 2023 08:11

The significant fall in both the share price and revenue of Blueprint Medicines Corporation could indicate unresolved issues within the company. The continued lack of profitability may also be a concern for long-term investors.

Loss-making Blueprint Medicines (NASDAQ:BPMC) Sheds a Further US$118m, Taking Total Shareholder Losses to 53% Over 3 Years

Analysts Notebook

Jul 8, 2022 06:47

Columns Top upgrades and downgrades on 7/8: PYPL, UPST, AAL, RCKT and more

Upgrades
• $Vita Coco (COCO.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $12 (from $10)
• $Diebold Nixdorf (DBD.US)$ : Wedbush Upgrades to Outperform from Neutral - PT $5
• $Eversource Energy (ES.US)$ : Guggenheim Upgrades to Buy from Neutral - PT $97 (from $92)
• $Howmet Aerospace (HWM.US)$ : Benchmark Upgrades to Buy from Neutral - PT $40
• $The Interpublic Group of Companies (IPG.US)$ : Wells Fargo Upgrades to Overweight...

Analysts Notebook

Jun 27, 2022 07:02

Columns Top upgrades and downgrades on 6/27: ETSY, CHWY, BBBY, GTLB and more

Upgrades
• $AutoZone (AZO.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $2,296 (from $1,969)
• $Chewy (CHWY.US)$ : Needham Upgrades to Buy from Hold - PT $55
• $National Vision (EYE.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $32 (from $31)
• $Fresenius Medical Care (FMS.US)$ : Jefferies Upgrades to Buy from Underperform - PT $33.70 (from $30.30)
• $Gitlab (GTLB.US)$ : Goldman Sachs Upgrades to Buy from Neutral - ...

No comment yet